The evaluation of present antileprosy compounds.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001500:BCG Vaccine; D002986:Clinical Trials as Topic; D003622:Dapsone / Q000627:therapeutic use; D004195:Disease Models, Animal; D004352:Drug Resistance, Microbial; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007916:Lepromin; D007918:Leprosy / Q000188:drug therapy* / Q000517:prevention & control; D008954:Models, Biological; D010619:Phenazines / Q000627:therapeutic use; D051381:Rats; D013449:Sulfonamides / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001500:BCG Vaccine; D007166:Immunosuppressive Agents; D010619:Phenazines; D013449:Sulfonamides; D007916:Lepromin; D003622:Dapsone